Glucagon-Like Peptide-1 7-36 Amide and Peptide YY from the L-Cell of the Ileal Mucosa Are Potent Inhibitors of Vagally Induced Gastric Acid Secretion in Man
- 1 January 1994
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 29 (6) , 501-505
- https://doi.org/10.3109/00365529409092462
Abstract
Wettergren A, Petersen H, 0rskov C, Christiansen J, Sheikh SP, Hoist JJ. Glucagon-like peptide-l 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 1994;29:501-505. Background: Glucagon-like peptide (GLP-1) 7-36 amide and peptide YY (PYY) from the L-cell of the ileal mucosa are potent inhibitors of gastric acid secretion in man. It is not clear, however, by which mechanism(s) they inhibit acid secretion. In dogs the inhibitory effect of PYY on acid secretion may be mediated mainly through neural pathways. The mechanism of action of GLP-1 might be similar. The aim of the present study was to examine the effects of GLP-1 might be similar. The aim of the present study was to examine the effects of GLP-1 and PYY on the vagally induced gastric acid secretion in man. Methods: A modified sham feeding technique, chew and spit, was used. Six healthy volunteers were randomly assigned to receive intravenous infusion of saline, GLP-1 (41 pmol/kg/h), or peptide YY (50 pmol/kg/h). Results: The infusion of GLP-1 and PYY resulted in plasma concentrations of 60 ± 9pmol/l and 84 ± 11 pmol/1, respectively. GLP-1 and PYY both significantly inhibited the integrated acid output by 67 ± 6% and 68 ± 9%, respectively, compared with the integrated outputs in a control experiment with saline infusion. Serum gastrin and plasma somatostatin concentrations remained unchanged during saline, GLP-1, and PYY infusions. Conclusions: GLP-1 and PYY are both potent inhibitors of the cephalic phase of acid secretion, indicating that at least part of the inhibitory effect of GLP-1 and PYY in man is mediated through neural pathways. Furthermore, the inhibitory effect seems to be independent of circulating concentrations of gastrin and somatostatin.Keywords
This publication has 20 references indexed in Scilit:
- Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in manDigestive Diseases and Sciences, 1993
- Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.Journal of Clinical Investigation, 1991
- Effect of Glucagon-Like Peptide-1 on Gastric Somatostatin and Gastrin Secretion in the RatScandinavian Journal of Gastroenterology, 1990
- Identification and characterization of glucagon‐like peptide‐1 7–36 amide‐binding sites in the rat brain and lungFEBS Letters, 1988
- Co-existence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic studyRegulatory Peptides, 1986
- Enterogastrone-like effect of peptide YY is vagally mediated in the dog.Journal of Clinical Investigation, 1986
- Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gutRegulatory Peptides, 1984
- On the accuracy of radioimmunological determination of somatostatin in plasmaRegulatory Peptides, 1982
- Ratio of Chymotrypsin to Trypsin in Human Duodenal AspirateDigestion, 1973
- Demonstration of the Humoral Agent in Fat Inhibition of Gastric Secretion.Experimental Biology and Medicine, 1930